Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 6, 2008, Pages 783-795

  DeNardo, Gerald L ^a   Natarajan, Arutselvan ^a   Hok, Saphon ^b   Mirick, Gary ^a   DeNardo, Sally J ^a   Corzett, Michele ^b   Sysko, Vladimir ^a   Lehmann, Joerg ^a   Beckett, Laurel ^c   Balhorn, Rod ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibodies; HLA DR; Imaging; Ligands; Lymphoma; Nanomolecules; Therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 3 [2 [[(3 CHLORO 5 TRIFLUOROMETHYL) 2 PYRIDINYL]OXY]ANILINO] 3 OXOPROPANIONIC ACID; 3 [2 [[(3 CHLORO 5 TRIFLUOROMETHYL) 2 PYRIDINYL]OXY]ANILINO] 3 OXOPROPANIONIC ACID LYSINE MACROGOL N BENZOYLARGINYL 4 AMINO BENZOIC ACID MACROGOL LYSINE; 5 LEUENKEPHALIN MACROGOL LYSINE DEOXYCHOLATE; 5 LEUENKEPHALIN MACROGOL LYSINE DEOXYCHOLATE 2 LYSINE MACROGOL; ANILINE DERIVATIVE; CYTOTOXIC AGENT; DABSYLVALYL MACROGOL LYSYLLYSINE 3 (2 [(3 CHLORO 5 TRIFLUOROMETHYL) 2 PYRIDINYL]OXY]ANILINO) 3 OXOPROPANIONIC ACID MACROGOL 4 [4 (4 CHLOROBENZYL)PIPERAZINO] 3 NITROBENZENECARBOXYLIC ACID MACROGOL MACROGOL MACROGOL 2 LYSYLLYSINE; DABSYLVALYL MACROGOL LYSYLLYSYL 3 (2 [(3 CHLORO 5 TRIFLUOROMETHYL) 2 PYRIDINYL]OXY]ANILINO] 3 OXOPROPANIONIC ACID MACROGOL 4 [4 (4 CHLOROBENZYL)PIPERAZINO] 3 NITROBENZENECARBOXYLIC ACID LYSINE; DABSYLVALYLLYSINE CYSTEIC ACID MACROGOL N BENZOYLARGINYL 4 AMINOBENZOIC ACID MACROGOL MACROGOL MACROGOL 2 CYSTEIC ACID LYSYLLYSINE; DABSYLVALYLLYSINE MACROGOL N BENZOYLARGINYL 4 AMINO BENZOIC ACID MACROGOL LYSINE; DABSYLVALYLLYSINE MACROGOL N BENZOYLARGINYL 4 AMINOBENZOIC ACID MACROGOL 2 LYSYLLYSINE; DABSYLVALYLLYSINE MACROGOL N BENZOYLARGINYL 4 AMINOBENZOIC ACID MACROGOL MACROGOL 2 LYSYLLYSINE; DABSYLVALYLLYSINE MACROGOL N BENZOYLARGINYL 4 AMINOBENZOIC ACID MACROGOL MACROGOL MACROGOL 2 LYSYLLYSINE; DABSYLVALYLLYSINE MACROGOL N BENZOYLARGINYL 4 AMINOBENZOIC ACID MACROGOL MACROGOL MACROGOL MACROGOL 2 LYSYLLYSINE; HLA DR ANTIGEN; HLA DR10 ANTIGEN; HLA DR10 MONOCLONAL ANTIBODY; IBRITUMOMAB TIUXETAN; LEUKOCYTE ANTIGEN; LIGAND; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; RADIOPHARMACEUTICAL AGENT; RECEPTOR PROTEIN; RITUXIMAB; TOSITUMOMAB I 131; TRIIODOTHYRONINE MACROGOL DEOXYCHOLATE MACROGOL 2 LYSYLLYSINE; TRIIODOTHYRONINE MACROGOL LYSINE DEOXYCHOLATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CANCER CELL CULTURE; CELL ACTIVITY; CELL ASSAY; CELL SELECTION; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER MODEL; CONFOCAL MICROSCOPY; DRUG POTENCY; DRUG TARGETING; DRUG TRANSPORT; HUMAN; HUMAN CELL; LIGAND BINDING; LYMPHOMA CELL; MOLECULAR IMAGING; MOLECULAR SIZE; MOLECULAR THERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RADIATION ABSORPTION; UPREGULATION; XENOGRAFT;

ANTIBODIES, MONOCLONAL; BIOMIMETIC MATERIALS; CELL LINE, TUMOR; CELL SURVIVAL; HLA-DR ANTIGENS; HUMANS; INDIUM RADIOISOTOPES; LEUKEMIA; LYMPHOMA; MOLECULAR MIMICRY; NANOPARTICLES; PEPTIDE FRAGMENTS; RADIOPHARMACEUTICALS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TISSUE DISTRIBUTION;

EID: 58549116710     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0589     Document Type: Article

References (35)

1. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized, controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453.
2. 131tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918.
3. DeNardo GL, Sysko VV, DeNardo SJ. Cure of incurable lymphoma. Int J Radiat Oncol Biol Phys 2006;66(Suppl 2):s46.
4. DeNardo GL, Tobin E, Chan K, et al. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and yttrium-90 HLA-DR antibodies. Clin Cancer Res 2005;11:7075.
5. Tobin E, DeNardo GL, Zhang N, et al. Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic antilymphoma effects in human lymphoma cell lines. Leuk Lymph 2007;48:944.
6. Zhang N, Khawli LA, Hu P, et al. Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors. Cancer Biother Radiopharm 2007;22:342.
7. Rose LM, Gunasekera AH, DeNardo SJ, et al. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 1996;43:26.
8. Rose LM, Deng CT, Scott S. Critical Lym-1 binding residues on polymorphic HLA-DR molecules. Mol Immunol 1999;36:789.
9. Kramer RH, Karpen JW. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature 1998;395:710.
10. Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins. Science 1997;278:497.
11. DeNardo GL, Natarajan A, Hok S, et al. Pharmacokinetic characterization in xenografted mice of a series of first generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma. J Nucl Med 2007;48:1338.
12. West J, Perkins J, Hok S, et al. Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells. Cancer Biother Radiopharm 2006;21:645.
13. Balhorn R, Hok S, Burke P, et al. Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: Initial application to lymphoma/leukemia. Clin Cancer Res 2007;13(Suppl 18):5621s.
14. DeNardo GL, Hok S, Natarajan A, et al. Characteristics of dimeric (bis) bidentate selective high-affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma. Int J Oncol 2007;31:729.
15. Hok S, Natarajan A, Balhorn R, et al. Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia. Bioconjug Chem 2007;18:912.
16. Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47:830.
17. Kuntz ID, Blaney JM, Oatley SJ, et al. A geometric approach to macromolecule-ligand interactions. J Mol Biol 1982;161:269.
18. Desjarlais RL, Sheridan RP, Seibel GL, et al. Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure. J Med Chem 1988;31:722.
19. Albrecht H, Cosman M, Ngu-Schwemlein M, et al. Recombinant expression of the b subunit of HLA-DR10 in the selection of novel lymphoma targeting molecules. Cancer Biother Radiopharm 2007;22:531.
20. Scatchard G. The attraction of proteins for small molecules and ions. Ann N Y Acad Sci 1947;51:660.
21. Goddu SM, Howell RW, Rao DV. Cellular dosimerty: Absorbed fractions for monoenrgetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartment. J Nucl Med 1994;35:303.
22. Ong GL, Elsamra SE, Goldenberg DM, et al. Single-cell cytotoxicity with radiolabeled antibodies. Clin Cancer Res 2001;7:192.
23. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Ann Rev Immunol 1997;15:821.
24. Leveille C, Cataigne JG, Charron D, et al. MHC class II isotype-specific signaling complex on human B-cells. Eur J Immunol 2002;32:2282.
25. Klemm JD, Schreiber SL, Crabtree GR. Dimerization as a regulatory mechanism in signal transduction. Annu Rev Immunol 1998;16:569.
26. Lane PJ, McConnell FM, Schieven GL, et al. The role of class II molecules in human B-cell activation. J Immunol 1990;144:3684.
27. Cescato R, Schulz S, Waser B, et at. Internalization of sst2, sst3, and sst5 receptors: Effects of somatostatin agonists and antagonists. J Nucl Med 2006;47:502.
28. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3246.
29. Ong GL, Mattes MJ. Processing of antibodies to the MHC class II antigen by B-cell lymphomas: Release of Fab-like fragments into the medium. Mol Immunol 1999;36:777.
30. 111In-labeled trastuzumab (herceptin) modified with nuclear localization sequences (NLS): An Auguer electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 2007;48:1357.
31. Zhang H, Tweel B, Tong L. Molecular basis for the inhibition of the carboxyltransferase domain of acetylcoenzyme-A carboxylase by haloxyfop and diclofop. Proc Natl Acad Sci U S A 2004;101:5910.
32. Yu C-R, Xu L-H, Tu S, et al. Sythesis and bioactivity of novel (3-chloro-5-(trifluoromethyl)pyridin-2-yloxy) phenyl containing acrylate and acrylonitrile derivatives. J Flourine Chem 2006;127:1540.
33. Zagnitko O, Jelenska J, Tevzadze G, et al. An isoleucine/ leucine residue in the carboxyltransferase domain of acety-CoA carboxylase is critical for interaction with aryloxyphenoxypropionate and cyclohexanedione inhibitors. Proc Natl Acad Sci U S A 2001;98:6617.
34. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nat Rev Cancer 2004;3:301.
35. Press OW, Howell-Clark J, Anderson S, et al. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994;83:1390.